L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
Keratosis pilaris
- 15min
- May. 2022
- Supported by
Therapeutic classes inducing this adverse event
BRAF inhibitor, RAF inhibitor
SIMPLIFIED GRADING
<10% BSA
No or few symptoms
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
SIMPLIFIED GRADING
10-30% BSA or >30% BSA with no or mild symptoms OR Limiting instrumental ADL OR
Psychosocial impact
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
SIMPLIFIED GRADING
>30% BSA with moderate or severe symptoms OR Limiting self care ADL
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events